Myovant Sciences ROCE 2024

Myovant Sciences Aktienanalyse

What does Myovant Sciences do?

Myovant Sciences Ltd. is a biotech company based in London that specializes in medications for women and men in various therapy areas. The company was founded in 2016 through the collaboration of Takeda Pharmaceutical and Roivant Sciences Ltd. After going public in 2016, Myovant is now listed on the NYSE. Myovant Sciences focuses on medications for the treatment of reproductive system disorders, hormone regulation, and urinary tract issues in aging individuals. The company is involved in research and development of new therapy options and currently has a pipeline of 5 projects focusing on the following indications: - Symptomatic uterine fibroids - Endometriosis - Prostate cancer - Reproductive disorders in women - Reproductive disorders in men A fibroid is a growth in the tissue of the uterus that often occurs in women of reproductive age and becomes symptomatic. Endometriosis is a chronic, painful condition where tissue that normally lines the uterus grows outside of it. Myovant can also offer treatment options for reproductive disorders in men. The founders of Myovant Sciences aim to improve patient care, especially for rare diseases that are often under-researched and lack effective treatment options. The company focuses on innovative technologies and customized solutions to differentiate themselves from other companies. This includes a focus on targeted therapy options tailored to specific patient groups. Myovant has embraced the motto "Don't become MVP (Most Valuable Player), become MVP - Medical Value Provider." The company works closely with clinics, universities, research institutions, and other companies in the industry to leverage the latest scientific developments and use them for the development of medical solutions for the market. Myovant offers a wide range of products, with a main focus on medications for women and men with severe reproductive system, hormone, and urinary tract disorders in aging individuals. An example of a product is Elagolix, which was developed in collaboration with Abbvie Inc. for the treatment of endometriosis-related pain in women. Myovant Sciences Ltd. is an innovative company with an ambitious goal of developing medications for patients suffering from reproductive system disorders, hormone regulation, and urinary tract issues in aging individuals. The company conducts research and development of products for specific indications in order to offer targeted therapy options for patients. Myovant works closely with numerous partners to develop innovative solutions for patients. Myovant Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Myovant Sciences's Return on Capital Employed (ROCE)

Myovant Sciences's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Myovant Sciences's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Myovant Sciences's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Myovant Sciences’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Myovant Sciences Stock

What is the ROCE (Return on Capital Employed) of Myovant Sciences this year?

The ROCE of Myovant Sciences is 0.4 undefined this year.

How has the ROCE (Return on Capital Employed) of Myovant Sciences developed compared to the previous year?

The ROCE of Myovant Sciences has increased by -46.29% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Myovant Sciences?

A high Return on Capital Employed (ROCE) indicates that Myovant Sciences has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Myovant Sciences?

A low ROCE (Return on Capital Employed) can indicate that Myovant Sciences has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Myovant Sciences impact the company?

An increase in the ROCE of Myovant Sciences can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Myovant Sciences affect the company?

A decrease in ROCE of Myovant Sciences can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Myovant Sciences?

Some factors that can affect Myovant Sciences's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Myovant Sciences so important for investors?

The ROCE of Myovant Sciences is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Myovant Sciences take to improve the ROCE?

To improve the ROCE, Myovant Sciences can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Myovant Sciences pay?

Over the past 12 months, Myovant Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Myovant Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Myovant Sciences?

The current dividend yield of Myovant Sciences is .

When does Myovant Sciences pay dividends?

Myovant Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Myovant Sciences?

Myovant Sciences paid dividends every year for the past 0 years.

What is the dividend of Myovant Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Myovant Sciences located?

Myovant Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Myovant Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Myovant Sciences from 6/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did Myovant Sciences pay the last dividend?

The last dividend was paid out on 6/6/2024.

What was the dividend of Myovant Sciences in the year 2023?

In the year 2023, Myovant Sciences distributed 0 USD as dividends.

In which currency does Myovant Sciences pay out the dividend?

The dividends of Myovant Sciences are distributed in USD.